New Charter Seeks to Build Global Support for Tolerance and Religious Freedom
10.12.2019 16:13:00 EET | Business Wire | Press release
This week some of the world’s most respected Islamic scholars, joined by experts from governments, civil society groups and other faiths, will launch a new effort to build global peace, based on tolerance and religious freedom.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191210005594/en/
New Charter Seeks to Build Global Support for Tolerance and Religious Freedom (Photo: AETOSWire)
At the sixth Assembly of the Forum for Promoting Peace in Muslim Societies, in Abu Dhabi, Shaykh Abdullah bin Bayyah, President of the Forum, will inaugurate the charter of the “New Alliance of Virtue”. Its text will be revealed and signed by its first signatories.
The charter aims to elevate religious freedom, cooperation, and tolerance from mere possibilities to necessary ethical commitments and legal obligations, especially in relation to the protection of places of worship whose attacks have threatened freedom of religion in many parts of the world.
This initiative draws direct inspiration from the earliest traditions of Islam.
The original Alliance of Virtue (hilf al-fudul) was established in early 7th century AD (late 1st century BH) Mecca, in the house of Abdullah ibn Judan.
Its purpose was to defend the weak and the innocent against the rapaciousness of those more powerful.
The Prophet of Islam, Mohammad, and the first of the Rightly Guided Caliphs, Abu Bakr, were both present when the Alliance was formed, though it was before Mohammad’s prophethood. He later praised it, saying: “I was present in the house of Ibn Judan when an alliance was formed, and were I to have been called upon by it in Islam, I would have answered its call.”
Last February in Washington D.C., H.E. Shaykh Abdullah bin Bayyah, President of the Forum for Promoting Peace, led a panel of over 200 individuals from the three Abrahamic faiths and others, comprising religious leaders and senior politicians in creating the modern Alliance of Virtue between religions.
The charter of the New Alliance of Virtue follows the model of the original, on a global scale. It brings together those of good-will for the benefit of humanity, an effort across religions to enable its members to live side-by-side in peace and happiness.
The charter doesn’t aim to bridge theological differences, members will instead cooperate based on a common theology of God-given human dignity, seeking virtue for the benefit of all.
Notes for Editors
The Forum for Promoting Peace in Muslim Societies is led by Shaykh Abdullah bin Bayyah, under the patronage of His Highness Sheikh Abdullah bin Zayed Al Nahyan, Minister for Foreign Affairs and International Cooperation. The Forum mines the best global Islamic scholarly expertise for solutions to the challenge of securing global peace. The Forum seeks to extinguish the fire of extremism that has spread throughout the world, with violence driven by erroneous and ill-informed interpretations of Islam. Participants will discuss and devise ways to challenge the extremism and politicisation which causes immense division and suffering.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191210005594/en/
Contact information
Forum for Promoting Peace in Muslim Societies
Zeshan Zafar, Executive Director, zeshan@peacems.com.
http://www.peacems.com/en/default.aspx
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
